HEALTH RELATED QUALITY OF LIFE (HRQOL) REPORTING IN ADULTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) RISK STRATIFIED BY MULTIPARAMETRIC MRI (MPMRI)
Author(s)
Marika Hancock, MSc1, Elizabeth Shumbayawonda, PhD1, Thuy Nguyen, MD2, Hildo Lamb, MD, PhD3, Alexander Thompson, PhD4;
1Perspectum, Oxford, United Kingdom, 2Perspectum, Texas, TX, USA, 3Leiden University, Leiden, Netherlands, 4AJT economics, Manchester, United Kingdom
1Perspectum, Oxford, United Kingdom, 2Perspectum, Texas, TX, USA, 3Leiden University, Leiden, Netherlands, 4AJT economics, Manchester, United Kingdom
OBJECTIVES: The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide and expected to have a prevalence of 55% by 2040. Metabolic dysfunction-associated steatohepatitis (MASH), a more serious form of MASLD, is expected to have a US prevalence of 5% by 2040. While the clinical outcomes are well understood, there is limited data on Health-Related Quality of Life (HRQoL) in MASH. Such data is important for evaluating disease burden and guiding clinical decision-making. This research aimed to identify the characteristics of HRQoL among MASH patients. The comparison was based on liver disease activity, assessed through multiparametric MRI (mpMRI), using corrected T1 (cT1) to characterise liver disease activity and Proton Density Fat Fraction (PDFF) for liver fat.
METHODS: 802 (female: 349, male: 453) patients with MASLD/MASH were recruited from specialist centres in Germany, the Netherlands, Portugal and the UK. Each participant completed EQ-5D-5L and VAS questionnaires across four time-points (baseline, 2-months, 6-months and 12-months). In this study, MASH was defined as cT1 and PDFF greater than or equal to 800ms and 10% respectively.
RESULTS: Compared to those with MASLD, MASH patients showed worse self-reported scores across all dimensions of the EQ-5D-5L and VAS and were 15% more likely to report issues with pain/discomfort. After adjusting for comorbidities (obesity, age, diabetes and hyperlipidaemia) MASH patients still showed poorer scores across all EQ-5D dimensions. Among patients with obesity, those with MASH were 35% more likely to report pain/discomfort compared to those with MASLD. Females reported lower scores across all dimensions with the biggest discrepancy in pain/discomfort, where females were 21% more likely to report problems than males.
CONCLUSIONS: Abnormal mpMRI metrics were an indicator of poorer Health-Related Quality of Life in MASH patients, especially for pain/discomfort. MASLD/MASH management should consider integrating both patient-reported outcomes and mpMRI alongside current tools in standard-of-care to inform clinical decisions.
METHODS: 802 (female: 349, male: 453) patients with MASLD/MASH were recruited from specialist centres in Germany, the Netherlands, Portugal and the UK. Each participant completed EQ-5D-5L and VAS questionnaires across four time-points (baseline, 2-months, 6-months and 12-months). In this study, MASH was defined as cT1 and PDFF greater than or equal to 800ms and 10% respectively.
RESULTS: Compared to those with MASLD, MASH patients showed worse self-reported scores across all dimensions of the EQ-5D-5L and VAS and were 15% more likely to report issues with pain/discomfort. After adjusting for comorbidities (obesity, age, diabetes and hyperlipidaemia) MASH patients still showed poorer scores across all EQ-5D dimensions. Among patients with obesity, those with MASH were 35% more likely to report pain/discomfort compared to those with MASLD. Females reported lower scores across all dimensions with the biggest discrepancy in pain/discomfort, where females were 21% more likely to report problems than males.
CONCLUSIONS: Abnormal mpMRI metrics were an indicator of poorer Health-Related Quality of Life in MASH patients, especially for pain/discomfort. MASLD/MASH management should consider integrating both patient-reported outcomes and mpMRI alongside current tools in standard-of-care to inform clinical decisions.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
P26
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities
Disease
SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Gastrointestinal Disorders